J
2.51
0.11 (4.58%)
| Previous Close | 2.40 |
| Open | 2.37 |
| Volume | 451,027 |
| Avg. Volume (3M) | 317,143 |
| Market Cap | 70,089,344 |
| Price / Book | 2.88 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -5.27 |
| Total Debt/Equity (MRQ) | 6.13% |
| Current Ratio (MRQ) | 4.31 |
| Operating Cash Flow (TTM) | -69.71 M |
| Levered Free Cash Flow (TTM) | -43.72 M |
| Return on Assets (TTM) | -56.50% |
| Return on Equity (TTM) | -101.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Jasper Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.5
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.27% |
| % Held by Institutions | 87.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 30 Jun 2025 | 928,964 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (UBS, 896.02%) | Buy |
| Median | 10.50 (318.33%) | |
| Low | 6.00 (JMP Securities, 139.04%) | Buy |
| Average | 13.00 (417.93%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 2.68 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 22 Sep 2025 | 7.00 (178.88%) | Buy | 2.54 |
| Evercore ISI Group | 22 Sep 2025 | 14.00 (457.77%) | Buy | 2.54 |
| JMP Securities | 22 Sep 2025 | 6.00 (139.04%) | Buy | 2.54 |
| UBS | 15 Aug 2025 | 25.00 (896.02%) | Buy | 3.11 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Sep 2025 | Announcement | Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants |
| 18 Sep 2025 | Announcement | Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants |
| 27 Aug 2025 | Announcement | Jasper Therapeutics to Present at Upcoming Investor Conferences |
| 13 Aug 2025 | Announcement | Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |